How were Albany Molecular Research's earnings last quarter?

Albany Molecular Research Inc (NASDAQ:AMRI) posted its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.21 by $0.14. The biotechnology company had revenue of $102.80 million for the quarter, compared to analysts' expectations of $107.20 million.

What other stocks do shareholders of Albany Molecular Research own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albany Molecular Research investors own include Casella Waste Systems (CWST) , Zevra Therapeutics (KMPH) , Teva Pharmaceutical Industries (TEVA) , Allergan (AGN) , INSYS Therapeutics (insy) , Taro Pharmaceutical Industries (TARO) , Altaba (AABA) , Analog Devices (ADI) , Abbott Laboratories (ABT) and Alkermes (ALKS) .

NASDAQ:AMRI

Albany Molecular Research (AMRI) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free AMRI Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $21.74
▼
$21.74
50-Day Range: $21.74
▼
$21.74
52-Week Range: $13.01
▼
$22.17

Volume: N/A
Average Volume: 872,120 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Albany Molecular Research alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Albany Molecular Research Stock (NASDAQ:AMRI)

Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

AMRI Stock News Headlines

April 9, 2024 | finance.yahoo.com

Denovo Biopharma Announces a Major Breakthrough in Treatment‑Resistant Depression with Precision Medicine

April 3, 2024 | finance.yahoo.com

Denovo Biopharma Announces a Major Breakthrough in Treatment-Resistant Depression with Precision Medicine

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 29, 2024 | msn.com

Cops who allegedly abducted Amri also involved in Pastor Koh’s disappearance, court told

February 26, 2024 | msn.com

Govt withdraws appeal over production of report on activist’s disappearance

February 21, 2024 | finance.yahoo.com

William S. Marth Joins CONTINUUS Pharmaceuticals Board of Directors, Bringing Commercial Leadership and Manufacturing Expertise to the Company

January 31, 2024 | bizjournals.com

Who and what you missed at the Elevate Albany: State of the Region Summit

January 23, 2024 | bizjournals.com

Curia Global puts Albany headquarters building up for sale

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

November 18, 2023 | msn.com

Suri has experimented with a different approach in 'Bad Manners'

November 15, 2023 | bizjournals.com

UAlbany, IBM announce new $20 million AI research collaboration

November 15, 2023 | finance.yahoo.com

In Silico Drug Discovery Market Size Worth USD 11.68 Billion in 2032 | Emergen Research

November 8, 2023 | benzinga.com

Global Small Molecule API Market to Reach US$ 174 Billion by 2033, Registering a CAGR of 4.1% | Future Market Insights, Inc.

November 5, 2023 | msn.com

Brain dead woman’s organs to save 6 lives in Odisha

September 30, 2023 | msn.com

Mubadala, BIA eye Manipal Hospitals stake

September 22, 2023 | msn.com

Manipal Hospitals acquires 84% stake in AMRI Hospitals to ramp up presence in Eastern India

September 21, 2023 | msn.com

Consolidation in India healthcare continues with Manipal acquiring majority stake in AMRI hospitals

September 13, 2023 | finance.yahoo.com

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

July 3, 2023 | forbes.com

Albany, GA

June 29, 2023 | finanznachrichten.de

Curia Global, Inc.: Curia wins 2023 Frost & Sullivan Customer Value Leadership Award

June 28, 2023 | health.usnews.com

Best Hospitals in Albany, NY

June 20, 2023 | finance.yahoo.com

Global Drug Discovery Outsourcing Market to 2030: Players Include Merck & Co, Thermos Fisher Scientific, Dalton Pharma Services and Oncodesign

June 14, 2023 | finance.yahoo.com

Vaccine Contract Manufacturing Global Market Report 2023: Sector to Reach $7 Billion by 2030 at a 3.9% CAGR

June 11, 2023 | msn.com

What is govt hiding in Amri case, say rights groups

June 10, 2023 | msn.com

Govt to study task force’s classified report on Amri’s disappearance

June 1, 2023 | benzinga.com

Global Drug Discovery Services Market Report 2023: Rising Focus on Drug Discovery Trials Bolsters Growth

May 16, 2023 | bizjournals.com

Albany has two star biotech companies. This company sees room for more.

See More Headlines

Receive AMRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albany Molecular Research and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/10/2016
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: N/A
Current Symbol: NASDAQ:AMRI
CUSIP: N/A
CIK: 1065087
Web: www.amriglobal.com
Phone: +1-518-4640279
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

William S. Marth
President, Chief Executive Officer, Director
Felicia Ladin
Chief Financial Officer, Senior Vice President, Treasurer
Lori M. Henderson Esq.
Senior Vice President, General Counsel, Secretary
Christopher M Conway
Senior Vice President - Discovery and Development and Global Commercial Sales
Bio & Compensation -
Milton Boyer
Senior Vice President - Drug Product Manufacturing
Bio & Compensation -
Steven R. Hagen Ph.D.
Senior Vice President - Manufacturing and Pharmaceuticals
George Svokos
Chief Commercial Officer and Senior Vice President, API
Jimmy Wang Ph.D.
Chief Information Officer
Bio & Compensation -
Thomas E. D' Ambra Ph.D.
Non-Executive Chairman of the Board
David H. Deming
Director

AMRI Stock Analysis - Frequently Asked Questions

How were Albany Molecular Research's earnings last quarter?: Albany Molecular Research Inc (NASDAQ:AMRI) posted its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.21 by $0.14. The biotechnology company had revenue of $102.80 million for the quarter, compared to analysts' expectations of $107.20 million.
What other stocks do shareholders of Albany Molecular Research own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Albany Molecular Research investors own include Casella Waste Systems (CWST), Zevra Therapeutics (KMPH), Teva Pharmaceutical Industries (TEVA), Allergan (AGN), INSYS Therapeutics (insy), Taro Pharmaceutical Industries (TARO), Altaba (AABA), Analog Devices (ADI), Abbott Laboratories (ABT) and Alkermes (ALKS).

This page (NASDAQ:AMRI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Albany Molecular Research (AMRI) Stock Price, News & Analysis

About Albany Molecular Research Stock (NASDAQ:AMRI)

AMRI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

AMRI Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info